^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Sarcoma
    Drug:Tibsovo (ivosidenib) (IDH1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chondrosarcoma...Conventional (Grades 1–3)...Useful in Certain Circumstances...Ivosidenib...(for susceptible IDH1 mutations)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Cholangiocarcinoma)
    New
    Excerpt:
    TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA-approved test with...Locally Advanced or Metastatic Cholangiocarcinoma...Locally advanced or metastatic cholangiocarcinoma who have been previously treated.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma.

    Published date:
    05/25/2023
    Excerpt:
    In pts with IDH1 mutated advanced conventional CS, IVO demonstrates manageable toxicity and durable disease control including long-term responses, extending several years for a proportion of pts.
    DOI:
    10.1200/JCO.2023.41.16_suppl.11532
    Trial ID:
    NCT02073994